Strategic Partnership Leverage the Galvani joint venture between GSK and Verily Life Sciences to position as a partner for neuromodulation therapies, highlighting access to established pharma/tech ecosystems and manufacturing capabilities.

Neuromodulation Focus Target opportunities around chronic disease management through neuromodulation platforms, aligning with Galvani's core mission and ongoing development such as splenic nerve stimulation for rheumatoid arthritis.

Clinical Trial Readiness Offer services or solutions that support regulatory compliance and quality systems (ISO 13485) and clinical trial execution for medical devices, aligning with Galvani’s standards and accelerated pathways.

Strategic Financing Signals Capitalize on the high-profile $615M investment and ongoing fundraising momentum to initiate conversations about scalable manufacturing, device integration, or data analytics partnerships that align with Galvani’s growth trajectory.

Tech & Ops Alignment Position capabilities in digital tooling, data interoperability, and manufacturing quality (Atlassian, WordPress, ISO 13485) to support Galvani’s product lifecycle, supplier management, and regulatory documentation needs.